175 related articles for article (PubMed ID: 22402754)
1. In silico investigation of interactions between human cannabinoid receptor-1 and its antagonists.
Kuang G; Hu G; Sun X; Li W; Liu G; Tang Y
J Mol Model; 2012 Aug; 18(8):3831-45. PubMed ID: 22402754
[TBL] [Abstract][Full Text] [Related]
2. Modeling of ligand binding to G protein coupled receptors: cannabinoid CB1, CB2 and adrenergic β 2 AR.
Latek D; Kolinski M; Ghoshdastider U; Debinski A; Bombolewski R; Plazinska A; Jozwiak K; Filipek S
J Mol Model; 2011 Sep; 17(9):2353-66. PubMed ID: 21365223
[TBL] [Abstract][Full Text] [Related]
3. In-silico designing and characterization of binding modes of two novel inhibitors for CB1 receptor against obesity by classical 3D-QSAR approach.
Khan N; Halim SA; Khan W; Zafar SK; Ul-Haq Z
J Mol Graph Model; 2019 Jun; 89():199-214. PubMed ID: 30908997
[TBL] [Abstract][Full Text] [Related]
4. Transmembrane helical domain of the cannabinoid CB1 receptor.
Shim JY
Biophys J; 2009 Apr; 96(8):3251-62. PubMed ID: 19383469
[TBL] [Abstract][Full Text] [Related]
5. Ligand-specific homology modeling of human cannabinoid (CB1) receptor.
Ai R; Chang CE
J Mol Graph Model; 2012 Sep; 38():155-64. PubMed ID: 23079645
[TBL] [Abstract][Full Text] [Related]
6. Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction.
Shim JY; Welsh WJ; Howlett AC
Biopolymers; 2003; 71(2):169-89. PubMed ID: 12767117
[TBL] [Abstract][Full Text] [Related]
7. Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis.
Floresta G; Apirakkan O; Rescifina A; Abbate V
Molecules; 2018 Aug; 23(9):. PubMed ID: 30200181
[TBL] [Abstract][Full Text] [Related]
8. Exploring the binding features of rimonabant analogues and acyclic CB1 antagonists: docking studies and QSAR analysis.
Cichero E; Menozzi G; Spallarossa A; Mosti L; Fossa P
J Mol Model; 2008 Dec; 14(12):1131-45. PubMed ID: 18696129
[TBL] [Abstract][Full Text] [Related]
9. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study.
Montero C; Campillo NE; Goya P; Páez JA
Eur J Med Chem; 2005 Jan; 40(1):75-83. PubMed ID: 15642412
[TBL] [Abstract][Full Text] [Related]
10. Computational investigation on the binding modes of Rimonabant analogs with CB1 and CB2.
Liu C; Yuan C; Wu P; Zhu C; Fang H; Wang L; Fu W
Chem Biol Drug Des; 2018 Sep; 92(3):1699-1707. PubMed ID: 29797785
[TBL] [Abstract][Full Text] [Related]
11. First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening.
Jain V; Saravanan P; Arvind A; Mohan CG
Chem Biol Drug Des; 2011 May; 77(5):373-87. PubMed ID: 21284830
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, biological evaluation, and comparative docking study of 1,2,4-triazolones as CB1 receptor selective antagonists.
Han S; Zhang FF; Xie X; Chen JZ
Eur J Med Chem; 2014 Mar; 74():73-84. PubMed ID: 24445310
[TBL] [Abstract][Full Text] [Related]
13. Discovery of cannabinoid-1 receptor antagonists by virtual screening.
Lee GN; Kim KR; Ahn SH; Bae MA; Kang NS
Bioorg Med Chem Lett; 2010 Sep; 20(17):5130-2. PubMed ID: 20667724
[TBL] [Abstract][Full Text] [Related]
14. An insilico approach to high altitude pulmonary edema - Molecular modeling of human beta2 adrenergic receptor and its interaction with Salmeterol & Nifedipine.
Chandramoorthi GD; Piramanayagam S; Marimuthu P
J Mol Model; 2008 Sep; 14(9):849-56. PubMed ID: 18512086
[TBL] [Abstract][Full Text] [Related]
15. In silico interaction analysis of cannabinoid receptor interacting protein 1b (CRIP1b) - CB1 cannabinoid receptor.
Singh P; Ganjiwale A; Howlett AC; Cowsik SM
J Mol Graph Model; 2017 Oct; 77():311-321. PubMed ID: 28918320
[TBL] [Abstract][Full Text] [Related]
16. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.
Janero DR; Korde A; Makriyannis A
Methods Enzymol; 2017; 593():217-235. PubMed ID: 28750804
[TBL] [Abstract][Full Text] [Related]
17. Crystal Structure of the Human Cannabinoid Receptor CB
Hua T; Vemuri K; Pu M; Qu L; Han GW; Wu Y; Zhao S; Shui W; Li S; Korde A; Laprairie RB; Stahl EL; Ho JH; Zvonok N; Zhou H; Kufareva I; Wu B; Zhao Q; Hanson MA; Bohn LM; Makriyannis A; Stevens RC; Liu ZJ
Cell; 2016 Oct; 167(3):750-762.e14. PubMed ID: 27768894
[TBL] [Abstract][Full Text] [Related]
18. 7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.
Rempel V; Volz N; Hinz S; Karcz T; Meliciani I; Nieger M; Wenzel W; Bräse S; Müller CE
J Med Chem; 2012 Sep; 55(18):7967-77. PubMed ID: 22916707
[TBL] [Abstract][Full Text] [Related]
19. Ligand supported homology modeling and docking evaluation of CCR2: docked pose selection by consensus scoring.
Kim JH; Lim JW; Lee SW; Kim K; No KT
J Mol Model; 2011 Oct; 17(10):2707-16. PubMed ID: 21213000
[TBL] [Abstract][Full Text] [Related]
20. Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists.
Lange JH; Kruse CG
Drug Discov Today; 2005 May; 10(10):693-702. PubMed ID: 15896682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
